COPENHAGEN, Denmark, Aug. 12, 2014 /PRNewswire/ -- Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has appointed Jan van de Winkel, Ph.D, President and Chief Executive Officer of Genmab, to its Board of Directors, effective immediately.
"We are pleased to add Jan to our Board," said Florian Schonharting, Forward Pharma's Co-Founder and Chairman of the Board of Directors. "As the CEO of a publicly traded biotechnology company, Jan has an impressive track record of leadership, as well as broad scientific, and academic expertise. We are confident that Jan's insights and contributions will be valuable to the Company and the Board."
"I look forward to leveraging my skill set and working closely with the management team and Board to build value for all of Forward Pharma's stakeholders," said Dr. van de Winkel. "I am excited about the potential FP187 has to positively impact the lives of people suffering from multiple sclerosis and other immune disorders."
Dr. van de Winkel is a co-founder of Genmab and currently serves as President and Chief Executive Officer. He has more than 20 years of experience in the therapeutic antibody field, is the author of over 300 scientific publications and has been responsible for more than 40 patents and pending patent applications. Dr. van de Winkel holds a professorship in Immunology at Utrecht University. He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. Prior to Genmab, Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe. He holds M.S. and Ph.D. degrees from the University of Nijmegen.
Andy Brimmer / Dan Katcher / Jennifer Beugelmans
Joele Frank, Wilkinson Brimmer Katcher
SOURCE Forward Pharma A/S